drugset / Trial / NCT00262275

Optimum Platelet Inhibition After Coronary Bypass Surgery

NCT00262275 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the effect of different dosages of aspirin on platelet aggregation and to determine the possible mechanisms of aspirin resistance, we intend to compare the effects of low, medium dose aspirin with clopidogrel (an alternative antiplatelet agent) in patients after coronary artery bypass surgery.

Timeline

Start
2002-07
Primary completion
2004-07
Completion
—

Outcome

Mixed primary results

paper Our primary outcome measure was platelet aggregation on day 5, expressed as percentage of baseline. PMID 15354104 ↗

paper The mean difference between the two arms was 42% (95% confidence interval 27%-56%) in favor of aspirin. PMID 15354104 ↗

paper Clopidogrel, unlike aspirin, did not inhibit platelet aggregation in the first 5 postoperative days PMID 15354104 ↗

paper Our primary outcome was the difference in platelet aggregation (day 5 - baseline) using 1 microg/ml of collagen. PMID 16716214 ↗

paper The baseline adjusted difference (low - medium) was 6% (95% CI -3 to 14; p = 0.19). PMID 16716214 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 100 mg —
Subject Aspirin Small molecule 325 mg —
Subject Clopidogrel Small molecule 75 mg —

Indications